 |
|
Novel gene therapy may lead to cure in hemophilia A patients
July 05, 2006Even hard to treat subset requiring expensive treatment
A discovery by Medical College of Wisconsin and BloodCenter of Wisconsin researchers in Milwaukee may be a key to a permanent genetic cure for hemophilia A patients, including a subset who do not respond to conventional blood transfusions. The study of genetically altered hemophilia mice is published in the July 2006 edition of The Journal of Clinical Investigation.
Hemophilia A affects about one in 5,000 males who lack the hereditary blood clotting protein, Factor VIII (FVIII). Traditional treatment requires infusion of synthetic FVIII two to three times a week to control bleeding episodes. However, about 30 percent of these patients develop antibodies to FVIII, selectively inactivating its clotting properties and negating its therapeutic role. Treatment for adults who have these inhibitory antibodies can cost over $1 million annually if there is a major bleeding episode.
"We developed a Trojan horse approach cloaking FVIII in a platelet so that it is undetected by the antibodies and its clotting properties are preserved until the platelet sticks to a damaged blood vessel and releases its stored protein which now includes FVIII.," explains senior author Robert R. Montgomery, M.D., senior investigator at the BloodCenter of Wisconsin and professor of pediatric hematology at the Medical College. He is also affiliated with the Children's Research Institute.
"This is truly a landmark development for hemophilia A patients," says hematologist, Joan Gill, M.D., professor of pediatric hematology at the Medical College, and director of the Comprehensive Center for Bleeding Disorders at the BloodCenter and Children's Hospital of Wisconsin. "We look forward to the day when basic research is completed and clinical trials can begin in patients."
Normally in an injury, platelets circulating in plasma—the liquid portion of the blood—stick to the site of the blood vessel wound, activating its surface and rapidly stopping bleeding. In hemophilia patients, infusion of FVIII replaces the missing clotting factor and enables normal cessation of bleeding. However, some 30 percent of patients see the FVIII as a foreign protein and mount antibodies to destroy it, rendering the FVIII treatment useless.
Newer FVIII treatment products that bypass this attack can run into $10,000 or $100,000 per treatment episode and costs for a patient may exceed $1 million annually. So far attempts at gene therapy for a permanent cure have not been successful.
According to the lead author, Qizhen Shi, M.D., Ph.D., an American Heart Association supported postdoctoral fellow, "Our team of scientists have developed an approach in mice that not only could make gene therapy successful for patients with hemophilia who don't have antibodies, but more importantly can be used to treat patients with antibodies.
"To get around the antibody attack on FVIII which occurs readily in plasma, we inserted a gene into a blood stem cell so that FVIII is produced and stored in blood platelets, hidden from view and attack, ready to release when a blood vessel is damaged, quickly enabling normal clotting before the antibodies can begin their attack. Our approach was very effective even in mice treated with five to ten thousand times the amount of antibody that would normally prevent treatment of a hemophilia patient with FVIII."
The new method will next be tested in larger animal models before clinical trials can begin in patients. Blood and bone marrow stem cells would be harvested from hemophilia patients in much the same way they are collected from bone marrow donors. A non-replicative virus containing the FVIII gene would be introduced into the stem cells from the patient. The FVIII engineered for production only in platelets would insert itself into the DNA of the stem cells. These same stem cells would then be given back to the donor patient and the stem cells would continue to make blood cells normally, releasing the life saving FVIII only when the platelets stick to a bleeding site of injury.
"This process would last for the rest of the patient's life and will work regardless of whether antibodies are present or absent," says Dr. Montgomery. "There will be many more studies needed to apply this approach in patients but this treatment could normalize bleeding for patients with hemophilia.
"What is most exciting about this first design of gene therapy for hemophilia is that it works not only for routine hemophilia but also for the 30 percent of patients who have developed inhibitory antibodies that make normal replacement treatment impossible," Dr. Montgomery concludes.
Medical College of Wisconsin
"We developed a Trojan horse approach cloaking FVIII in a platelet so that it is undetected by the antibodies and its clotting properties are preserved until the platelet sticks to a damaged blood vessel and releases its stored protein which now includes FVIII.," explains senior author Robert R. Montgomery, M.D., senior investigator at the BloodCenter of Wisconsin and professor of pediatric hematology at the Medical College. He is also affiliated with the Children's Research Institute.
"This is truly a landmark development for hemophilia A patients," says hematologist, Joan Gill, M.D., professor of pediatric hematology at the Medical College, and director of the Comprehensive Center for Bleeding Disorders at the BloodCenter and Children's Hospital of Wisconsin. "We look forward to the day when basic research is completed and clinical trials can begin in patients."
Normally in an injury, platelets circulating in plasma—the liquid portion of the blood—stick to the site of the blood vessel wound, activating its surface and rapidly stopping bleeding. In hemophilia patients, infusion of FVIII replaces the missing clotting factor and enables normal cessation of bleeding. However, some 30 percent of patients see the FVIII as a foreign protein and mount antibodies to destroy it, rendering the FVIII treatment useless.
Newer FVIII treatment products that bypass this attack can run into $10,000 or $100,000 per treatment episode and costs for a patient may exceed $1 million annually. So far attempts at gene therapy for a permanent cure have not been successful.
According to the lead author, Qizhen Shi, M.D., Ph.D., an American Heart Association supported postdoctoral fellow, "Our team of scientists have developed an approach in mice that not only could make gene therapy successful for patients with hemophilia who don't have antibodies, but more importantly can be used to treat patients with antibodies.
"To get around the antibody attack on FVIII which occurs readily in plasma, we inserted a gene into a blood stem cell so that FVIII is produced and stored in blood platelets, hidden from view and attack, ready to release when a blood vessel is damaged, quickly enabling normal clotting before the antibodies can begin their attack. Our approach was very effective even in mice treated with five to ten thousand times the amount of antibody that would normally prevent treatment of a hemophilia patient with FVIII."
The new method will next be tested in larger animal models before clinical trials can begin in patients. Blood and bone marrow stem cells would be harvested from hemophilia patients in much the same way they are collected from bone marrow donors. A non-replicative virus containing the FVIII gene would be introduced into the stem cells from the patient. The FVIII engineered for production only in platelets would insert itself into the DNA of the stem cells. These same stem cells would then be given back to the donor patient and the stem cells would continue to make blood cells normally, releasing the life saving FVIII only when the platelets stick to a bleeding site of injury.
"This process would last for the rest of the patient's life and will work regardless of whether antibodies are present or absent," says Dr. Montgomery. "There will be many more studies needed to apply this approach in patients but this treatment could normalize bleeding for patients with hemophilia.
"What is most exciting about this first design of gene therapy for hemophilia is that it works not only for routine hemophilia but also for the 30 percent of patients who have developed inhibitory antibodies that make normal replacement treatment impossible," Dr. Montgomery concludes.
Medical College of Wisconsin
Hemophilia Current Events and Hemophilia News RSSResearch highlights need to address hemophilia in developing world
When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
Jumping genes discovery 'challenges current assumptions'
Jumping genes do most of their jumping, not during the development of sperm and egg cells, but during the development of the embryo itself.
Gene therapy technique thwarts cancer by cutting off tumor blood supply
University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor's blood and nutrient supply.
Gene therapy demonstrates benefit in patients with rheumatoid arthritis
Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past.
Redesigned protein accelerates blood clotting
Researchers have made several, subtle changes in the structure of a key protein, dramatically increasing its ability to drive blood clotting, according to a study published in a December edition of the Journal of Thrombosis and Haemostasis.
Mapping a clan of mobile selfish genes
Much of human DNA is the genetic equivalent of e-mail spam: short repeated sequences that have no obvious function other than making more of themselves.
Blood-clotting protein modified for people with hard-to-treat hemophilia
Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A.
UF researchers develop improved gene therapy agent
Replacing one amino acid on the surface of a virus that shepherds corrective genes into cells could be the breakthrough scientists have needed to make gene therapy a more viable option for treating genetic diseases such as hemophilia, University of Florida researchers say.
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume.
More Hemophilia Current Events and Hemophilia News Articles
 |
Hemophilia (Genes and Disease) by Michelle Raabe (Author) For many people, bumping into a chair or getting a paper cut means momentary pain, followed by quick healing. But for those with hemophilia, a disease that renders its sufferers unable to clot blood effectively and control hemorrhaging after minor injuries, the healing time can be much more arduous. Resulting from mutations in genes that code for blood proteins necessary for clotting, hemophilia is an ancient, hereditary disease that usually affects males and can be classified as severe, moderate, or mild. "Hemophilia", a detailed and easy-to-read guide filled with informative stories of the disease's history, strives to educate readers about the science of hemophilia, while emphasizing how people with this disease can live full and productive lives. The development and technology behind... |
 |
Textbook of Hemophilia by Christine A. Lee (Editor), Erik E. Berntorp MD PhD (Editor), W. Keith Hoots MD (Editor), Louis M. Aledort MD (Editor) The only up-to-date definitive reference source on hemophilia This book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults, Haemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There will also be a section on musculoskeletal aspects of haemophilia as well as newer developments such as gene therapy and rare bleeding disorders. Textbook of Hemophilia is ideal for: Why Buy This... |
|
World Federation of Hemophilia Membership by World Federation of Hemophilia | |
 |
Understanding Hemophilia (Home Use) Part of the award winning public television series Healthy Body/Healthy Mind. Bleeding due to a cut or wound can be a little scary at times, especially if your child is a hemophiliac. Hemophiliacs lack specific blood proteins known as clotting factors that our bodies need to control bleeding following an injury. Fortunately, there is far more hope than ever before for these young patients. This episode features individuals with hemophilia who are successfully managing the disease in a manner that allows them to enjoy active and productive lives. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Blood Saga: Hemophilia, AIDS, and the Survival of a Community, Updated Edition With a New Preface by Susan Resnik (Author) For thousands of years boys known as "bleeders" faced an early, painful death from hemophilia. Dubbed "the Royal Disease" because of its identification with Queen Victoria, the world's most renowned carrier, hemophilia is a genetic disease whose sufferers had little recourse until the mid-twentieth century. In the first book to chronicle the emergence and transformation of the hemophilia community, Susan Resnik sets her story within our national political landscapewhere the disease is also a social, psychological, and economic experience. Blood Saga includes many players and domains: men with hemophilia and their families, medical personnel, science researchers, and the author herself, who was Director of Education of the National Hemophilia Foundation in the ... |
 |
Hemophilia and Your Child: Interactive Education and Support for Parents by Bayer, Inc. Healthcare Division Hemophilia and Your Child is an interactive program designed to provide education and support to parents raising children with hemophilia. This CD-Rom has been developed by a group of hemophilia nurses, physiotherapists, physicians, parents, and Bayer in collaboration with the Canadian Hemophilia Society. This program integrates a variety of learning styles and adapts to the user's pace and interests. The content was developed with the help of the advisory board and a team of medical researches and writers. A feature of this CD is video clips of parents discussing the challenges of living with hemophilia, providing realistic peer education. |
|
An Unexpected Life Living with Hemophilia 58 minute documentary that captures a slice of living history and creates and inspirational message about surviving with hemophilia and related bleeding disorders. | |
 |
Ft. Hemophilia Drive-In Eight Lanes To Nowhere Bill Frenzer and Ogden Edsl (Primary Contributor) |
|
Hemophilia Awareness Ribbon Mouse Pad by MyHeritageWear.com | |
 |
The Gift of Experience: Conversations About Hemophilia by Laura Gray (Author), Christine Chamberlain (Author) "The Gift of Experience" captures the lives and perspectives of twenty-one men, born with hemophilia, and their caregivers, in ways that other resources have failed to do. In vital and personal stories, their accounts capture the impact of the dramatic advances in the treatment of the disease as well as the challenges of chronic pain and joint damage. The conversations also include discussions of the HIV and hepatitis C infections resulting from the tainted blood supply between the late 1960s and the mid-1980s. Laura Gray and Christine Chamberlain have done a tremendous job weaving these oral histories into a narrative that allows their subjects to speak for themselves. "The Gift of Experience" is a 'must read' for anyone interested in the illness and disability experiences of people... |
| © 2009 BrightSurf.com |